Edition:
United States

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.26USD
25 May 2017
Change (% chg)

-- (--)
Prev Close
$1.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
117,634
52-wk High
$2.00
52-wk Low
$0.74

DRRX.OQ

Chart for DRRX.OQ

About

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)

Overall

Beta: 1.89
Market Cap(Mil.): $178.88
Shares Outstanding(Mil.): 141.97
Dividend: --
Yield (%): --

Financials

  DRRX.OQ Industry Sector
P/E (TTM): -- 138.86 17.42
EPS (TTM): -0.25 -- --
ROI: -118.87 2.17 -5.45
ROE: -516.16 0.04 -4.73

BRIEF-Durect Corp, Sandoz AG sign U.S. development and commercialization agreement for posimir

* Durect Corp - co and Sandoz AG, a division of Novartis, have signed a development and commercialization agreement for U.S. for posimir

May 11 2017

BRIEF-Durect Q1 revenue $4.6 million

* Durect Corporation announces first quarter 2017 financial results and provides corporate update

May 10 2017

CORRECTED-Durect, Novartis' Sandoz ink deal to develop non-opioid pain drug

May 8 Durect Corp said on Monday it signed an up to $293 million deal with Swiss drugmaker Novartis AG's Sandoz unit to develop and market Durect's experimental non-opioid pain relief therapy, posimir, in the United States.

May 08 2017

BRIEF-Durect and Sandoz signs a $293 mln development and commercialization agreement for Posimir

* Durect and Sandoz have signed a $293 million development and commercialization agreement for Posimir (saber-bupivacaine) covering the United States

May 08 2017

NASH: The next untapped pharma market gives investors many options

Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020. | Video

Apr 24 2017

UPDATE 1-NASH: The next untapped pharma market gives investors many options

April 24 Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.

Apr 24 2017

BRIEF-Durect presents data from a Phase 1B study of DUR-928 in nonalcoholic steatohepatitis (NASH)

* Durect announces presentation of data from a Phase 1B study of DUR-928 in nonalcoholic steatohepatitis (NASH)

Apr 24 2017

RPT-INSIGHT-NASH: The next untapped pharma market gives investors many options

April 24 Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.

Apr 24 2017

INSIGHT-NASH: The next untapped pharma market gives investors many options

April 24 Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.

Apr 24 2017

BRIEF-Durect Corporation posts Q4 loss per share $0.06

* Durect Corporation announces fourth quarter and full year 2016 financial results and update of programs

Mar 14 2017

More From Around the Web

Earnings vs. Estimates